Communiqués Eloxx Pharmaceuticals, Inc.

Actions

ELOX

US29014R2022

Temps Différé OTC Markets Autres places de cotation 20:36:12 27/06/2024			Varia. 5j.	Varia. 1 janv.
0,69 ^USD	0,00%		+0,03%	-42,50%

13/03	Almirall et Eloxx Pharmaceuticals concluent un accord exclusif de licence du ZKN-013 pour des maladies dermatologiques rares	CI
13/03	Almirall signe un accord de licence avec Eloxx Pharmaceuticals pour le traitement des maladies de la peau	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates	16/04	AQ
Eloxx Pharmaceuticals : Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases	13/03	PU
Eloxx Pharmaceuticals Reports Third Quarter 2023 Financial and Operating Results and Provides Business Update	13/11	AQ
Eloxx Pharmaceuticals : October 2023 Investor Presentation	10/10/23	PU
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction	10/10/23	AQ
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria	09/10/23	AQ
Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules	19/09/23	AQ
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	18/09/23	AQ
Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013	07/09/23	AQ
Eloxx Pharmaceuticals : Management Change - Form 8-K	30/08/23	PU
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	15/08/23	AQ
Eloxx Pharmaceuticals : August 2023 Investor Presentation	14/08/23	PU
Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update	14/08/23	AQ
Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome	14/08/23	AQ
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement	03/08/23	AQ
Eloxx Pharmaceuticals : July 2023 Investor Presentation	17/07/23	PU
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit	10/07/23	AQ
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study	29/06/23	AQ
Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02	28/06/23	AQ
ELOXX PHARMACEUTICALS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	23/06/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Eloxx Pharmaceuticals, Inc.

Actions

ELOX

US29014R2022

Communiqués

Filtres